Satsuma Pharmaceuticals, Inc. Email Format
Pharmaceutical ManufacturingCalifornia, United States11-50 Employees
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for migraine and other debilitating conditions. Its lead candidate, STS101, is a nasal powder formulation of dihydroergotamine intended to treat acute migraine episodes. Based in South San Francisco, California, the company operates within the pharmaceutical manufacturing sector and pursues clinical development to expand options for acute migraine management. The company targets people who suffer from migraine and related conditions as its primary patients. A recent development is that abstracts from its clinical program were selected for presentation at the American Headache Society's 68th Annual Scientific Meeting in 2026, indicating ongoing clinical work. This reflects continued engagement with the scientific community while STS101 remains in development.